Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF.

ABSTRACT:

Background

Sodium-glucose linked transporter type 2 (SGLT-2) inhibition has been shown to reduce cardiovascular mortality in heart failure independently of glycemic control and prevents the onset of atrial arrhythmias, a common co-morbidity in heart failure with preserved ejection fraction (HFpEF). The mechanism behind these effects is not fully understood, and it remains unclear if they could be further enhanced by additional SGLT-1 inhibition. We investigated the effects of chronic treatment with the dual SGLT-1&2 inhibitor sotagliflozin on left atrial (LA) remodeling and cellular arrhythmogenesis (i.e. atrial cardiomyopathy) in a metabolic syndrome-related rat model of HFpEF.

Methods

17 week-old ZSF-1 obese rats, a metabolic syndrome-related model of HFpEF, and wild type

SUBMITTER: Bode D 

PROVIDER: S-EPMC7792219 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature